Ece Cali Daylan, MD, PhD (@ececalidaylan) 's Twitter Profile
Ece Cali Daylan, MD, PhD

@ececalidaylan

Thoracic oncologist 🫁 @wustl @sitemancenter via @montefioreNYC @einsteinmed

ID: 1487472904031899650

linkhttps://scholar.google.com/citations?user=TYMqrVEAAAAJ&hl=en&oi=ao calendar_today29-01-2022 17:09:48

79 Tweet

331 Followers

578 Following

Lauren Averett Byers, MD (@laurenbyersmd) 's Twitter Profile Photo

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. MD Anderson Cancer Center Thank you to the study team and all of our investigators, patients and families. ASCO #ASCO24

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI?  Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> Thank you to the study team and all of our investigators, patients and families. <a href="/ASCO/">ASCO</a> #ASCO24
Balazs Halmos (@balazshalmosmd) 's Twitter Profile Photo

Hem/onc-there’s no core curriculum. The entire experience is an elective Outstanding class Montefiore Health System Albert Einstein College of Medicine - Official has chosen this elective as life mission-wish you’ll best of luck with half staying in Monte circles/others moving on to great things as far as Wash U/Jefferson!

Montefiore Health System (@montefiorenyc) 's Twitter Profile Photo

Congratulations to the three researchers recognized by the Montefiore Staff & Alumni Association! They received the Henry L. Moses Awards in recognition of their exceptional clinical papers and contributions to healthcare. #MonteProud Albert Einstein College of Medicine - Official

Congratulations to the three researchers recognized by the Montefiore Staff &amp; Alumni Association! They received the Henry L. Moses Awards in recognition of their exceptional clinical papers and contributions to healthcare. #MonteProud <a href="/EinsteinMed/">Albert Einstein College of Medicine - Official</a>
ASCO TECAG (@ascotecag) 's Twitter Profile Photo

🚨Are you ➡️graduating⬅️ Hematology-Fellowship this month and worried about losing access to ASCO-SEP before your boards? ⏳ Contact ➡️[email protected] once your subscription expires to obtain an extended 12-month subscription for $49, instead of $275! 🌟

🚨Are you ➡️graduating⬅️ Hematology-Fellowship this month and worried about losing access to <a href="/ASCO/">ASCO</a>-SEP before your boards? ⏳

Contact ➡️professionaldevelopment@asco.org once your subscription expires to obtain an extended 12-month subscription for $49, instead of $275!  🌟
Andy Minn (@andyjminn) 's Twitter Profile Photo

Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w E. John Wherry Divij Caitlin Foley Melina Marmarelis Joshua Bauml, MD et al! 1/13

Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w <a href="/EJohnWherry/">E. John Wherry</a> <a href="/divijmathew/">Divij</a> Caitlin Foley <a href="/MMarmarelis/">Melina Marmarelis</a> <a href="/Jbauml/">Joshua Bauml, MD</a> et al! 1/13
Society for Immunotherapy of Cancer (@sitcancer) 's Twitter Profile Photo

#SITC SCION 2025 equips participants with insights into #cancer #immunotherapy #clinical #trials & offers guidance from industry leaders. Expand your network & refine your clinical trial protocol from Feb. 11–14, 2025 in Austin. Apply by July 22: go.sitcancer.org/4cAoQjC

#SITC SCION 2025 equips participants with insights into #cancer #immunotherapy #clinical #trials &amp; offers guidance from industry leaders. Expand your network &amp; refine your clinical trial protocol from Feb. 11–14, 2025 in Austin. Apply by July 22: go.sitcancer.org/4cAoQjC
Ece Cali Daylan, MD, PhD (@ececalidaylan) 's Twitter Profile Photo

Learning from a mentor indeed never ends, whether it's diving into oncology or savoring Nola food! 🐊 Incredibly lucky to have had Balazs guiding me at the start of my thoracic oncology journey and excited to have him as my first visitor in St. Louis!

Rami Manochakian MD, FASCO Cancer Education (@rmanochakian) 's Twitter Profile Photo

🔥🚨OncoAlert HOT OFF THE PRESS. Just presented at the presidential symposium IASLC #WCLC24 Results of #HARMONi2 trial of #Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 >1%. ✅ Significant ⬆️mPFS 11.14 vs. 5.82 months (HR 0.51) #Benefit

🔥🚨<a href="/OncoAlert/">OncoAlert</a> HOT OFF THE PRESS.

Just presented at the presidential symposium <a href="/IASLC/">IASLC</a> #WCLC24 

Results of #HARMONi2 trial of 
#Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 &gt;1%.

✅ Significant ⬆️mPFS
11.14 vs. 5.82 months (HR 0.51)

#Benefit
IASLC (@iaslc) 's Twitter Profile Photo

Four leading scientists were honored Saturday at #WCLC24 for their pioneering efforts in thoracic oncology. Read more in #ILCN: bit.ly/47jCgOQ @juliebrahmer #LCSM

Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Very nice discussion on relapsed #SCLC by Dr. Anjali Rohatgi at #WCLC24. ADCs showing promise and easier to deliver than a BiTE like tarlatamab. No clear biomarker but encouraging efficacy. But we need randomized data to provide clear perspective.

Very nice discussion on relapsed #SCLC by Dr. <a href="/Arohatgi/">Anjali Rohatgi</a> at #WCLC24. ADCs showing promise and easier to deliver than a BiTE like tarlatamab. No clear biomarker but encouraging efficacy. But we need randomized data to provide clear perspective.
JessicaJLinMD (@jessicajlinmd) 's Twitter Profile Photo

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by Alexander Drilon MD ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by <a href="/alexdrilon/">Alexander Drilon MD</a> 
✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs)
✅ ORR 35% in pts post-lorlatinib (in which
Myriam Chalabi (@myriamchalabi) 's Twitter Profile Photo

Honored and excited to be scientific co-chair of #ESMO25 together with Toni Choueiri, MD With FabriceAndre as incoming ESMO - Eur. Oncology president on our side we will be giving it our all! See you in #Berlin 🙏 Rebecca Dent for a fantastic, practice-changing #ESMO24. We learn from the best ❗️❗️

Honored and excited to be scientific co-chair of #ESMO25 together with <a href="/DrChoueiri/">Toni Choueiri, MD</a> 
With <a href="/FAndreMD/">FabriceAndre</a> as incoming <a href="/myESMO/">ESMO - Eur. Oncology</a> president on our side we will be giving it our all! See you in #Berlin 
🙏 <a href="/RebeccaDSing/">Rebecca Dent</a> for a fantastic, practice-changing #ESMO24. We learn from the best ❗️❗️
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

#ESMO24 Lung mini-orals🔥

Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis:
- 292pts
- 15% reduction in RP
- no long-term steroid tox 

No need for ph III, could do tomorrow 
#ESMOAmbassadors #ESMO24 <a href="/myESMO/">ESMO - Eur. Oncology</a>
TLC Conference (@tlcconference) 's Twitter Profile Photo

The 3rd Annual #TexasLung25 will feature even more faculty than ever before! Mark your calendar to join us April 10-12, 2025 for this 2-day CME/CE meeting in Austin, TX. Be part of the discussions and meet leading thoracic oncologists. #MedEd #LungCancer #CME #CE

The 3rd Annual #TexasLung25 will feature even more faculty than ever before! Mark your calendar to join us April 10-12, 2025 for this 2-day CME/CE meeting in Austin, TX. Be part of the discussions and meet leading thoracic oncologists.  #MedEd #LungCancer #CME #CE
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

The #WCLC24 Photo Gallery caught some great pics of the incredibly knowledgable contestants on our Meet The Expert Quiz Show! Thanks again to Drs. Natasha Leighl, Ben Solomon Ece Cali Daylan, MD, PhD Giannis Mountzios JessicaJLinMD Zac and Brinda Gupta!

The #WCLC24 Photo Gallery caught some great pics of the incredibly knowledgable contestants on our Meet The Expert Quiz Show! Thanks again to Drs. Natasha Leighl, <a href="/bensolomon1/">Ben Solomon</a> <a href="/ececalidaylan/">Ece Cali Daylan, MD, PhD</a> <a href="/g_mountzios/">Giannis Mountzios</a> <a href="/JessicaJLinMD/">JessicaJLinMD</a> <a href="/zaccoyne/">Zac</a> and Brinda Gupta!
Mikkael A. Sekeres MD, MS (@mikkaelsekeres) 's Twitter Profile Photo

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…